secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001193125-26-089871
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics Q4 net loss $23M; cash $152.4M; FDA clears TSC-102 INDs; plans Phase 3 trial Q2 2026
--------------------------------------------------------------------------------

- Net loss $23.0M in Q4 2025 vs $35.8M Q4 2024; revenue $2.6M vs $0.7M.
- Cash and equivalents $152.4M as of Dec 31, 2025; funds operations into H2 2027.
- FDA cleared INDs for TSC-102-A01 and TSC-102-A03 targeting CD45 for heme malignancies post-HCT.
- Enrollment completed in Cohort C of ALLOHA heme trial with commercial-ready manufacturing; initial data due Q2 2026.
- Discontinued solid tumor PLEXI-T trial; advancing in vivo TCR-T engineering and autoimmunity programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526089871/0001193125-26-089871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526089871/tcrx-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-089871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer